[go: up one dir, main page]

EA201391155A1 - Ингибитор катепсина с - Google Patents

Ингибитор катепсина с

Info

Publication number
EA201391155A1
EA201391155A1 EA201391155A EA201391155A EA201391155A1 EA 201391155 A1 EA201391155 A1 EA 201391155A1 EA 201391155 A EA201391155 A EA 201391155A EA 201391155 A EA201391155 A EA 201391155A EA 201391155 A1 EA201391155 A1 EA 201391155A1
Authority
EA
Eurasian Patent Office
Prior art keywords
katepsin
inhibitor
butenamides
amino
formula
Prior art date
Application number
EA201391155A
Other languages
English (en)
Other versions
EA023168B1 (ru
Inventor
Кристофер Э. Нейпп
Майкл Р. Палович
Original Assignee
Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46638952&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201391155(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед filed Critical Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед
Publication of EA201391155A1 publication Critical patent/EA201391155A1/ru
Publication of EA023168B1 publication Critical patent/EA023168B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Раскрываются 4-амино-2-бутенамиды формулы (I), обладающие фармакологической активностью, фармацевтические композиции, содержащие их, и способы лечения заболеваний, опосредуемых ферментом катепсином С, таких как хроническое обструктивное заболевание легких.
EA201391155A 2011-02-11 2012-02-09 Ингибитор катепсина с EA023168B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161441840P 2011-02-11 2011-02-11
PCT/US2012/024428 WO2012109415A1 (en) 2011-02-11 2012-02-09 Cathepsin c inhibitors

Publications (2)

Publication Number Publication Date
EA201391155A1 true EA201391155A1 (ru) 2014-01-30
EA023168B1 EA023168B1 (ru) 2016-04-29

Family

ID=46638952

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201391155A EA023168B1 (ru) 2011-02-11 2012-02-09 Ингибитор катепсина с

Country Status (24)

Country Link
US (2) US8841463B2 (ru)
EP (1) EP2672821B9 (ru)
JP (1) JP5931929B2 (ru)
KR (1) KR20140048857A (ru)
CN (1) CN103491777B (ru)
AR (1) AR085163A1 (ru)
AU (1) AU2012214405B2 (ru)
BR (1) BR112013020510A2 (ru)
CA (1) CA2827157A1 (ru)
CL (1) CL2013002325A1 (ru)
CO (1) CO6741219A2 (ru)
DO (1) DOP2013000182A (ru)
EA (1) EA023168B1 (ru)
ES (1) ES2583091T3 (ru)
IL (1) IL227814A0 (ru)
MA (1) MA34961B1 (ru)
MX (1) MX2013009279A (ru)
PE (1) PE20140999A1 (ru)
PH (1) PH12013501665A1 (ru)
SG (1) SG192669A1 (ru)
TW (1) TW201302736A (ru)
UY (1) UY33905A (ru)
WO (1) WO2012109415A1 (ru)
ZA (1) ZA201306074B (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014091443A1 (en) 2012-12-13 2014-06-19 Glaxo Group Limited Cathepsin c inhibitors for treating cystic fibrosis, non-cystic fibrosis bronchiectasis, and anca-associated vasculitis
NO2699580T3 (ru) 2014-01-24 2018-02-24
EA201891674A1 (ru) * 2016-02-12 2019-01-31 Фармаксис Лтд. Ингибиторы лизилоксидаз, представляющие собой индольные и азаиндольные производные галогеналлиламина, и их применения
KR20250022023A (ko) 2022-06-13 2025-02-14 알리벡시스 가부시키가이샤 아자사이클로알킬카보닐 환상 아민 화합물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2622581B1 (fr) * 1987-11-03 1990-02-16 Inorgan Sa Rech Develop Pharm Nouveaux derives de l-proline, leur preparation et leurs applications biologiques
CN1240355A (zh) * 1996-05-01 2000-01-05 伊莱利利公司 蛋白激酶c抑制剂增强溶癌剂和放射治疗的临床功效的用途
US6232299B1 (en) 1996-05-01 2001-05-15 Eli Lilly And Company Use of protein kinase C inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy
US6214799B1 (en) 1996-05-14 2001-04-10 Agouron Pharmaceuticals, Inc. Antipicornaviral compounds and methods for their use and preparation
AU2002232558A1 (en) * 2000-12-12 2002-06-24 Corvas International, Inc. Compounds, compositions and methods for treatment of parasitic infections
US8114871B2 (en) * 2007-04-12 2012-02-14 Pfizer Inc. 3-amido-pyrrolo[3,4-C]pyrazole-5(1H,4H,6H) carbaldehyde derivatives
WO2010128324A1 (en) 2009-05-07 2010-11-11 Astrazeneca Ab Substituted 1-cyanoethylheterocyclylcarboxamide compounds 750
UY32827A (es) * 2009-08-12 2011-02-28 Glaxo Group Ltd Inhibidores de catepsina c
WO2012119941A1 (en) 2011-03-04 2012-09-13 Prozymex A/S Peptidyl nitrilcompounds as peptidase inhibitors

Also Published As

Publication number Publication date
PE20140999A1 (es) 2014-09-11
CA2827157A1 (en) 2012-08-16
CO6741219A2 (es) 2013-08-30
EP2672821A4 (en) 2014-08-06
JP5931929B2 (ja) 2016-06-08
AR085163A1 (es) 2013-09-11
EP2672821A1 (en) 2013-12-18
US20140364476A1 (en) 2014-12-11
IL227814A0 (en) 2013-09-30
UY33905A (es) 2012-08-31
NZ614540A (en) 2015-03-27
EP2672821B9 (en) 2016-11-23
AU2012214405A1 (en) 2013-04-18
CL2013002325A1 (es) 2014-01-03
US20130324584A1 (en) 2013-12-05
KR20140048857A (ko) 2014-04-24
MA34961B1 (fr) 2014-03-01
DOP2013000182A (es) 2014-03-16
US8841463B2 (en) 2014-09-23
BR112013020510A2 (pt) 2016-07-12
US9187461B2 (en) 2015-11-17
WO2012109415A1 (en) 2012-08-16
AU2012214405B2 (en) 2015-07-23
CN103491777A (zh) 2014-01-01
EA023168B1 (ru) 2016-04-29
EP2672821B1 (en) 2016-04-20
ES2583091T3 (es) 2016-09-19
TW201302736A (zh) 2013-01-16
CN103491777B (zh) 2015-05-06
PH12013501665A1 (en) 2019-07-17
JP2014506577A (ja) 2014-03-17
ZA201306074B (en) 2014-04-30
MX2013009279A (es) 2013-10-28
SG192669A1 (en) 2013-09-30

Similar Documents

Publication Publication Date Title
CY1120866T1 (el) Παρεμποδιστες dna-pk
EA201491028A8 (ru) Способ получения замещенных 5-фтор-1н-пиразолопиридинов
EA201491012A1 (ru) Гетероциклические ингибиторы глютаминазы
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
EA201590975A1 (ru) Ингибиторы prmt5 и их применение
EA201490724A1 (ru) Замещенные соединения тетрагидроизохинолина в качестве ингибиторов фактора xia
CO6551666A2 (es) Macrociclos como inhibidores del factor de coagulacion (fxia)
EA201892339A2 (ru) Несиалированный выделенный полипептид, способ получения указанного полипептида и фармацевтическая композиция для лечения воспалительного заболевания
GEP20186885B (en) Novel compounds
EA201391719A1 (ru) Хиназолиновые производные для лечения вирусных инфекций и дальнейших заболеваний
EA201691803A1 (ru) Ингибиторы калликреина плазмы человека
EA201390711A1 (ru) Гидроксиамидные соединения пиримидина в качестве ингибиторов деацетилаз белков и способы их применения
EA201071057A1 (ru) Производные азетидина и циклобутана как ингибиторы jak-киназ
EA201391615A1 (ru) Дейтерированные потенциаторы cftr
EA201500278A1 (ru) Пиразолилхиназолиновые ингибиторы киназы
EA201100311A1 (ru) Амидные производные гетероарилов и их применение в качестве активаторов глюкокиназы
EA201301019A1 (ru) Бензодиоксановые ингибиторы продуцирования лейкотриена
BR112013001753A2 (pt) método para preparar uma composição d einter-alfa-inibidor (iaip) eriquecida de plasma, solução aquosa de iaip, e, método para tratar uma doença ou distúrbio associado com disfunção de iaip e associado com atividadede protease de serina no plasma aumentada.
EA201490423A1 (ru) СПОСОБЫ И КОМПОЗИЦИИ, ОТНОСЯЩИЕСЯ К p62, ДЛЯ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ РАКА
MD4556B1 (ru) Соединения ингибирующие активность катехол О-метилтрансферазы
EA201491247A1 (ru) Производные дигидробензооксазина и дигидропиридооксазина
EA201300250A1 (ru) Оксадиазольные ингибиторы продуцирования лейкотриена
DK2243772T3 (da) Hidtil ukendte P2X7R-antagonister og deres anvendelse
MX347692B (es) Inhibidores del virus de la hepatitis c.
EA201491013A1 (ru) Пиразиновые ингибиторы киназы

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU